Alnox

Alnox is a pre-clinical stage biotechnology company developing a proprietary platform for the targeted delivery of nitric oxide (NO) to treat vascular and inflammatory diseases. Founded as a spin-out from the University of Pittsburgh, the company leverages the expertise of world-renowned researchers in nitric oxide biology to address the limitations of current NO-based therapies. The Alnox platform is designed to provide localized, controlled release of NO, thereby maximizing therapeutic efficacy in diseased tissues while avoiding systemic side effects like hypotension. The company's primary focus areas include sickle cell disease, where NO deficiency plays a central role in vaso-occlusive crises, and pulmonary arterial hypertension. By restoring NO signaling in a targeted manner, Alnox aims to provide a new standard of care for patients with high-need vascular disorders. The company is currently advancing its lead programs through pre-clinical development with support from regional venture partners.